<DOC>
	<DOCNO>NCT00024375</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness DHA-paclitaxel treating patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>DHA-Paclitaxel Treating Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine tumor response rate , duration response , time disease progression patient metastatic carcinoma pancreas treat DHA-paclitaxel . - Determine overall survival patient treated drug . - Determine toxicity profile drug patient . - Assess quality life patient treated drug . OUTLINE : This multicenter study . Patients receive DHA-paclitaxel IV 2 hour day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Quality life assess baseline , every 2 course , completion treatment . Patients follow every 3 month . PROJECTED ACCRUAL : A total 21-50 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm carcinoma pancreas Metastatic disease Measurable disease Lesions within previously irradiate field consider measurable No islet cell tumor , lymphoma , sarcoma pancreas No known clinical evidence CNS metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No uncontrolled ventricular arrhythmia No myocardial infarction within past 3 month No superior vena cava syndrome Neurologic : No peripheral neuropathy great grade 1 No uncontrolled major seizure disorder No spinal cord compression Other : No concurrent serious infection require parenteral therapy No unstable serious concurrent medical condition No prior malignancy except : Curatively treat nonmelanoma skin cancer carcinoma situ cervix OR Other cancer curatively treat surgery alone recur 5 year No psychiatric disorder would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No prior chemotherapy metastatic disease Prior adjuvant chemoradiotherapy allow At least 28 day since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except megestrol Radiotherapy : See Disease Characteristics Prior adjuvant chemoradiotherapy allow At least 28 day since prior largefield radiotherapy recover No concurrent radiotherapy Surgery : At least 14 day since prior major surgery recover Other : No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>